Mineralys Therapeutics recently announced that the detailed results of the critical Phase 2 clinical trial Advance HTN have been published in the New England Journal of Medicine. The experiment aims to evaluate the efficacy of the investigational therapy lorundrostat in patients with poorly controlled hypertension or refractory hypertension. The experimental results showed that lorundrostat reduced the average 24-hour dynamic systolic blood pressure of patients by 11.5 mmHg compared to baseline at week 4; At the 12th week of treatment, the average 24-hour dynamic systolic blood pressure of patients decreased by 13.9-15.4 mmHg, which was significantly better than the placebo group (7.4 mmHg).
Hypertension is the leading cause of cardiovascular disease and death worldwide. Although there are various antihypertensive drugs available for patients to use, less than 50% of patients can achieve blood pressure standards after medication. In about 30% of hypertensive patients, an imbalance in aldosterone level regulation is an important factor driving hypertension. Aldosterone can promote physiological processes such as water sodium retention, inflammation, arteriosclerosis and oxidative stress. Therefore, reducing aldosterone synthesis by inhibiting aldosterone synthase is one of the important research directions for the treatment of hypertension, especially refractory hypertension.
Lorundrostat is an orally administered highly selective aldosterone synthase inhibitor. It reduces aldosterone levels by inhibiting the CYP11B2 enzyme responsible for aldosterone production. In vitro studies have shown that lorundrostat selectively inhibits aldosterone synthase 374 times more than cortisol synthase, and can inhibit aldosterone synthesis without affecting cortisol levels. In hypertensive subjects, plasma aldosterone concentration can be reduced by about 70%.
The Advance HTN trial is a randomized, double-blind, placebo-controlled phase 2 clinical study evaluating the efficacy and safety of lorundrostat as an adjunct therapy to two or three standard antihypertensive drug background treatments in adult patients with poorly controlled or refractory hypertension. In terms of secondary endpoints, compared to placebo, the lorundrostat group showed superior blood pressure lowering effects at week 4 of treatment: the lorundrostat group had an average decrease in systolic blood pressure of 11.5 mmHg, while the placebo group had a value of 6.2 mmHg.
In March of this year, Mineralys announced that lorundrostat had also reached its primary endpoint in another critical phase 3 clinical trial, Launch HTN. The company plans to further disclose data from the Launch HTN trial at the upcoming medical conference. In addition, the ongoing Transformer HTN open label extension trial allows participants to continue receiving lorundrostat treatment to obtain more safety and efficacy data.
<Reprinted from WuXi AppTec>





![72287-26-4 [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)](/uploads/41320/small/72287-26-4b28f5.jpg?size=331x0)

![67292-36-8 [1,1'-Bis(diphenylphosphino)ferrocene]dichlorocobalt(II)](/uploads/41320/small/67292-36-8afec7.jpg?size=331x0)